The sema buying landscape flipped on February 21, 2026. That's the day the FDA pulled all Ozempic and Wegovy formulations off the drug shortage list and called the shortage resolved, which killed most of the compounding access that had been keeping sema in the $150–350/month range through tele-doc platforms since 2023. Enforcement discretion for 503A pharmacies ended April 22, 2026. For 503B outsourcing facilities, it ended May 22, 2026 (FDA guidance, 2026).
If you're asking where to buy semaglutide in 2026, the honest answer is shorter than it was six months ago. There are still legit lanes. The thing that matters most before you pull the trigger is knowing which lanes are actually legal and which vendors are still shipping like nothing changed.
Key Takeaways
- —The FDA declared the semaglutide shortage over February 21, 2026 — compounding enforcement for 503A pharmacies started April 22, with narrow exceptions for people with specific clinical needs.
- —Legal lanes in 2026: brand Ozempic/Wegovy with a script, Novo Nordisk's NovoCare programme, or grandfathered compounded sema for specific patient needs (excipient allergy, unusual dose).
- —SURMOUNT-5 (72-week head-to-head) showed sema at 13.7% weight loss vs tirz at 20.2% — that gap matters if you're picking a lane.
- —Compare sema against tirz on the Next Pep comparison tool before your tele-doc visit.
Shortage list status is what gave 503A and 503B pharmacies legal cover to compound sema in the first place. While a drug sits on that list, compounders can prepare it to plug supply gaps. The moment the FDA calls the shortage over, that exception evaporates.
One narrow lane is still open. Pharmacies can compound sema if it's "not essentially a copy" of the brand product, meaning there's a clinically meaningful difference tied to a specific patient need. Think excipient allergy formulations, off-grid concentrations for unusual dosing, or combos with another clinically indicated component. General-purpose compounded sema for weight loss doesn't qualify anymore (Burr & Forman, 2026).
1. Brand Ozempic (T2D indication). Ozempic is FDA-approved for glycaemic control in type 2 diabetes. Off-label use for weight loss is legal under physician discretion, but insurance coverage for that off-label path is hit-or-miss. List price runs about $935/month. Insurance or manufacturer coupons knock it way down.
2. Brand Wegovy (weight management indication). Wegovy carries the FDA approval for chronic weight management. List price is about $1,350/month. Coverage has improved since 2023 but it's still inconsistent payer to payer. NovoCare offers savings for people who qualify.
3. Rybelsus (oral sema). The pill version is FDA-approved for T2D and gets you sema without pinning. Bioavailability is brutal compared to subq, around 1% absorption vs roughly 89% subcutaneous, which is why the dose ladders 3 mg to 7 mg to 14 mg to hit therapeutic levels. It's not a 1:1 swap for subq Wegovy at matched doses.
4. Grandfathered compounded sema for specific clinical needs. This is the narrow lane that's still open through 503A pharmacies. Documented excipient allergy (think polysorbate 80 in Ozempic/Wegovy), an off-grid dose that isn't commercially available, or another specific clinical justification can qualify you. The prescriber documents the rationale and the pharmacy has to be able to articulate the clinical distinction without hand-waving.
A note on the gray market: research-grade sema from international suppliers is cheaper than anything above. It's also unverified, untested batch-to-batch, not backed by a pharmacy COA, and outside any regulatory framework. People do it. People also get bunk vials. YMMV.
If you're picking between sema and tirz in 2026, SURMOUNT-5 is the trial that actually answers the question. The 72-week RCT pinned max-dose tirz (20 mg) head-to-head against max-dose sema (2.4 mg) in adults with obesity. Tirz produced 20.2% mean weight loss. Sema produced 13.7% (NEJM, 2025).
That gap is real. In a head-to-head RCT, that's the kind of evidence the field rarely gets. Tirz hits the GIP receptor on top of GLP-1, and the dual mechanism produces more weight loss on average. Whether the gap matters for you personally comes down to your response, what you can tolerate, and what you can actually access at a price that works.
Sema's longer track record is the counterweight. It's been in widespread clinical use since 2021 vs tirz since 2022. Cardiovascular outcome data (SUSTAIN, SELECT) is deeper for sema. If you carry CV risk, that published CV data may matter more than the weight differential.
The Next Pep comparison tool puts sema and tirzepatide side by side, mechanism, PK, and dosing in one view, so you walk into the prescriber conversation with the data already in hand.
Anecdotally, the GI side effect profile is the wildcard. Some people who couldn't get past sulfur burps and nausea on sema do fine on tirz, and the reverse happens too. Trial averages don't tell you which one your gut will tolerate. A dose hold or split dose at the start of titration is often the lever, regardless of which molecule you're on.
If you've got a documented clinical need that qualifies you for compounded sema under the narrow lane, the quality checklist is the same as it ever was.
API source. The active pharmaceutical ingredient has to come from an FDA-registered manufacturer. Ask straight up. A compliant 503A will answer without flinching.
Batch-specific COA. HPLC purity and concentration on the actual batch you're getting, not a generic spec sheet. Sema's MW is 4113.58 Da, which is what mass spec should hit.
PCAB accreditation. The strongest quality signal you can ask for on a 503A.
Sterility and endotoxin testing. You're putting this subq. Sterility and endotoxin burden aren't optional.
Knowing what sema actually does, GLP-1 mechanism, PK, the SURMOUNT-5 read against tirz, and what the shortage resolution did to access, makes the tele-doc consult go a lot smoother. The peptide library covers both sema and tirz with full molecular and clinical summaries in one neutral, cross-referenced view. The comparison tool puts them side-by-side across mechanism, trial data, and dosing before any platform tries to steer you.
For planning the actual injection protocol, the dosing calculator handles the reco maths. Enter your prescribed concentration and target dose and it spits out exact draw volume in mL and syringe units. Next Pep is independent. No tele-doc referrals, no pharmacy affiliation, no commercial relationship with any compounder. It's the research layer you use before talking to anyone who profits from the sale.
Compounded sema got squeezed hard once the FDA called the shortage resolved. General-purpose compounding for weight management isn't permitted under 503A anymore. Narrow exceptions still apply for people with specific clinical needs: documented excipient allergies, unusual dose requirements, or clinically justified combo formulations. Ask any pharmacy still compounding to spell out their legal basis, and check whether they've caught an FDA warning letter.
With insurance and a valid script, Ozempic or Wegovy co-pays land between $25 and $200/month through NovoCare. Without insurance, brand runs about $935/month (Ozempic) and $1,350/month (Wegovy). Compounded sema is narrow now and reserved for specific clinical needs. For a lot of people, the cheaper math points at tirzepatide via 503A compounding, which is still available at $229–349/month.
SURMOUNT-5, the 72-week head-to-head RCT, put tirz at 20.2% mean weight loss vs sema at 13.7% at max approved doses. Tirz's dual GIP/GLP-1 mechanism produces more weight loss on average. Sema has deeper CV outcome data, and individual GI tolerability is its own thing independent of trial averages. Use the comparison tool and run both past a prescriber.
Yes. This is one of the qualifying lanes that's still legal under the "not essentially a copy" standard. Documented allergy to polysorbate 80 or another excipient in the brand formulations means a 503A can compound a version that drops that excipient. Your prescriber documents the clinical rationale. PCAB-accredited pharmacies are best set up to handle the paperwork trail correctly.
Sema (Ozempic/Wegovy/Rybelsus) is an FDA-approved prescription medication. Compounding access is now restricted following the end of the drug shortage in February 2026.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.